New York State Department Of Health Provides Clinical Laboratory Evaluation Program Test Approval To Niki BioSolutions' DiamiR Biosciences Subsidiary For Its APOE Genotyping Test
Niki BioSolutions, Inc. (NASDAQ: NIKI) ("Niki BioSolutions" or the "Company"), a clinical-stage life sciences company focused on developing advanced genomic and biomarker testing solutions, today
New York approved Niki BioSolutions' new DNA test for health screening. This shows progress toward selling the test and earning money from it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.